# Trace Neuroscience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/trace-neuroscience

- Industry: Biotechnology
- Headquarters: South San Francisco, US
- Website: www.traceneuro.com
- Total disclosed funding: $101M
- Latest round: Series A (Nov 12, 2024)
- Investors on record: 4

## About

Based in California, US, and founded in 2024, Trace Neuroscience, Inc. operates as a biopharmaceutical company that specializes in surgical imaging technology for people living with neurodegenerative diseases. In November 2024, Trace Neuroscience, Inc. raised USD 101 million in a Series A funding led by Third Rock Ventures, with participation from Atlas Venture, GV, and RA Capital Management. As of November 2024, Eric Green is the CEO of the company. 

Trace Biosciences focuses on developing innovative imaging agents designed to enhance surgical procedures by providing real-time visualization of nerves. The company’s primary product, Nerve Trace, is engineered to highlight all nerves within the body after a single intravenous injection. This technology integrates seamlessly with existing clinical imaging systems and employs fluorescence to deliver immediate visual feedback, aiming to reduce the incidence of surgical nerve damage. By addressing the critical needs of surgeons and enhancing surgical outcomes, Trace Biosciences targets hospitals and surgical facilities globally, particularly in advanced healthcare markets such as the United States and Europe.

Trace Biosciences generates revenue through direct sales of its flagship product, Nerve Trace, to healthcare providers and surgical institutions. The business model is structured around B2B transactions, where surgical hospitals and clinics purchase the imaging agents as essential tools for procedures that risk nerve damage. 

Trace Neuroscience plans to use its proceeds from November 2024 funding to the application of genomic medicine in neurodegenerative conditions. This will support the development of upcoming products intended to enhance surgical outcomes and expand into new markets such as Europe and Asia by 2025.

## Funding rounds

- Series A, Nov 12, 2024, $101M — Atlas Venture, Third Rock Ventures, GV, RA Capital Management

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series A
- Third Rock Ventures (https://capitalatlas.ai/funds/third-rock-ventures) — Series A
- GV (https://capitalatlas.ai/funds/gv) — Series A
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A